BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats

Toxicology and Applied Pharmacology

Volumn 190, Issue 1, 2003, Pages 9-16

  Bardos G ^a   Moricz K ^a   Jaszlits, L ^b   Rabloczky, G ^b   Tory, K ^b   Racz I ^b   Bernath S ^b   Sumegi B ^c   Farkas, B ^c   Literati Nagy B ^b   Literati Nagy P ^b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b N Gene Research Laboratories   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

BGP 15; Cisplatin; Modulation of PARP activity; Nerve conduction velocity; Peripheral sensory neuropathy; Poly(ADP ribose) polymerase (PARP) enzyme; Prevention of neuropathy; Taxol; Toxic effects of antitumor drugs

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; PACLITAXEL; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; ENZYME INHIBITION; IN VIVO STUDY; MALE; MOTOR NERVE; NERVE CONDUCTION; NERVE STIMULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; RAT; SCIATIC NERVE; SENSORY NERVE; SENSORY NEUROPATHY;

RATTUS NORVEGICUS;

EID: 17344382828     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(03)00155-8     Document Type: Article

References (49)

1. 1 exposure. Acta Biol. Hung. 53:2002;413-422.
2. Bárdos G., Móricz K., Jaszlits L., Rablóczky G., Rácz I., Tory K., Bernáth S., Literáti-Nagy P. Protective effects of BGP-15 on cytostatic-drug induced neuroptahy in rats assessed by measuring nerve conductance. Eur. J. Neurosci. 12:(Suppl. 11):2000;231.
3. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., Neckers L.M. Taxol induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56:1996;1851-1854.
4. Bürkle A., Chen G., Küpper J.H., Grube K., Zeller W.J. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis. 14:1993;559-561.
5. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer a randomised placebo-controlled trial . J. Clin. Oncol. 13:1995;26-32.
6. Cassidy J., Paul J., Soukop M., Habeshaw T., Reed N., Parkin D., Kaye S.B. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother. Pharmacol. 41:1998;161-166.
7. Cavaletti G., Cascinu S., Venturino P., Tedeshi M., Tredici G. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res. 16:1996;3149-3160.
8. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negru O., Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of Paclitaxel in the rat. Neurotoxicology. 18:1997;137-146.
9. Cavaletti G., Tredici G., Pizzini G., Marimiroli P., Fabbrica D., Minola R. Morphologic, morphometric and toxicologic evaluation of the effect of cisplatin alone or in combination with gluthatione on the rat nervous system. Clin. Neuropathol. 11:1992;169-175.
10. Chen G., Pan Q.C. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Cancer Chemother. Pharmacol. 22:1988;303-337.
11. Chen G., Zeller W.J. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. Cancer Chemother. Pharmacol. 26:1990;3741.
12. Cliffer K.D., Siuciak J.A., Carson S.R., Radley H.E., Park J.S., Lewis D.R., Zlotchenko E., Nguyen T., Garcia K., Tonra J.R., Stambler N., Cedarbaum J.M., Bodine S.C., Linsday R.M., DiStefano P.S. Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann. Neurol. 43:1998;46-55.
13. Czuba Z.P., Krol W., Hasinski P., Nowowiejska A. The effects of taxol (paclitaxel) on chemoluminescence of neutrophils, macrophages and J.774.2 cell line. Acta Biochim. Pol. 45:1998;103-106.
14. De Koning P., Neijt J.P., Jennekens F.G., Gispen W.-H. Org-2766 protects from cisplatin-induced neurotoxicity in rats. Exp. Neurol. 97:1987;746-750.
15. Di Re F., Bohm S., Oriana S., Spatti G.B., Zumino F. High dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann. Oncol. 4:1990;55-61.
16. Eliasson M.J.L., Sampei K., Mandir A., Hurn P., Traystman R.J., Bao J., Pieper A., Wang Z.Q., Dawson T.M., Snyder S., Dawson W.L. Poly(ADP-ribose)polymerase gene disruption renders mice resistent to cerebral ischemia. Nat. Med. 3:1997;1089-1095.
17. Gandura D.R., Natishas W.A., Adelson M.D., Lichtman S., Podezuski E.S., Yanovich S., Homesley F.D., Braly P., Ritch P.S., Reich S.D., McCarrol K., Hoff J.V. Randiomised placebo-controlled multicentre evaluation of diethylolithiol-carbamate for chemoprotection against cisplatin-induced toxicities. J. Clin. Oncol. 13:1995;490-496.
18. Gao W.-Q., Dybdal N., Shinsky N., Murnane A., Schmelzer C., Siegel M., Keller G., Hefti F., Philips H.S., Winslow J.W. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 38:1995;30-37.
19. Gerritsen van der Hoop R., De Koning P., Boven E., Neijt J.P., Jennekens F.G.I., Gispen W.-H. Efficacy of the neuropeptide ORG-2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur. J. Cancer. 23:1988;637-642.
20. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 58:1996;1253-1255.
21. Hamers F.P.T., Gerritsen van der Hoop R.G., Steerenburg P.A., Neijt J.P., Gispen W.-H. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol. Appl. Pharmacol. 111:1991;514-522.
22. Hamers, F.P.T., Pette, C., Neijt, J.P., Gispen, W-H. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur. J. Pharmacol. 177-178 (1993).
23. Henkels K.M., Turchi J.J. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and - independent pathways in cisplatin-resistant and - sensitive human ovarian cancer cell lines. Cancer Res. 59:1999;3077-3083.
24. Ibrado A.M., Liu L., Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 57:1997;1109-1115.
25. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., Homesley H., Belpomme D., Glick J. Amifostine pretreatment for protection against ciclophosphamide-induced and cisplatin induced toxicities results of a randomised, controlled trial in patients with advanced ovarian cancer . J. Clin. Oncol. 14:1996;2101-2112.
26. Kennedy M., Szabó C., Salzman A.L. Poly-(ADP-ribose)synthetase activation mediates increased permeability induced by peroxinitrite in Caco-2-BBc cells. Gastroenterology. 114:1998;510-518.
27. Kukorelli, T., Világi, I., 1998. Laboratory Practices in Physiology. Eötvös, Budapest, (in Hungarian).
28. Lipton R.B., Apfel S.C., Dutcher J.P., Rosenberg R., Kaplan J., Berger A., Einzig A.I., Armstrong D.K., Donehower R.C. Taxol produces a predominantly sensory neuropathy. Neurology. 39:1989;368-373.
29. Matsuda H., Tanaka T., Takaham A.U. Cisplatin generates superoxide anion by interaction with DNA in a cell free system. Biochem. Biophys. Res. Commun. 203:1994;1175-1181.
30. McGowan A.J., Ruiz-Ruiz M.C., Gorman A.M., Lopes-Rivas A., Cotter T.G. Reactive oxygen intermediates (ROI) common mediators of poly(ADP-ribose)polymerase (PARP) cleavage . FEBS Lett. 392:1996;299-304.
31. McGuire W.P., Hoskins W.J., Brady M.F., Kugera P.R., Partrige E.E.P., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxal and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
32. McKeage M.J., Haddad G.G., Ding L., Galettis P., Screnci D., Zhuang L., Bagule y B.C. Neuroprotective interactions in rats between paclitaxel and cisplatin. Oncol. Res. 11:1999;287-293.
33. Mollmann J.E., Glover D.J., Hogan N., Furman R. Cisplatin neuropathy. Cancer. 61:1988;2192-2195.
34. Pae H.O., Jun C.D., Yoo J.C., Kwak H.J., Lee S.J., Kook Y.A., Park R.K., Chung H.T. Enhancing and priming of macrophages for superoxide anion production by taxol. Immunopharmacol. Immunotoxicol. 20:1998;27-37.
35. Rácz I., Tory K., Gallyas F., Berente Z., Ösz E., Jaszlits L., Bernath S., Sümegi B., Rabloczky G.y., Literáti-Nagy P. BGP-15 a novel poly(ADP-ribose)polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63:2002;1099-1111.
36. Roberts J.A., Jenison E.L., Kim K., Clarke-Pearson D., Langlebean A. A randomized, multicentre, double-blind, placebo-controlled dose-finding study of Org-2766 in the prevention or delay of cisplatin induced neuropathies in women with ovarian cancer. Gynecol. Oncol. 67:1997;172-177.
37. Russel J.W., Windenbank A.J., McNiven M.A., Brat D.J., Brimijoin W.S. Effect of cisplatin induced neurotoxicity. Brain Res. 676:1995;258-267.
38. Schiff P.B., Fant J., Horowitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
39. Smyth J.F., Bowman A., Perren T., Wilkinson P., Prescott R.J., Quinn K.J., Tedeschi M. Glutathione, reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin results of a double-bind randomised trial . Ann. Oncol. 8:1997;569-573.
40. Stanley E.F. Sensory and motor nerve conduction velocity and the latency of the H reflex during growth of the rat. Exp. Neurol. 71:1981;497-506.
41. Sümegi B., Rabloczky G.y., Rácz I., Tory K., Bernath S., Várbíró G., Gallyas F., Literáti-Nagy P. Protective effect of poly (ADP-ribose)polymerase inhibitors against cell damage induced by antiviral and anti-cancer drugs. Szabo C. Cell Death (The Role of PARP). 2000;167-183 CRC Press, New York.
42. Szabados E., Literati-Nagy P., Farkas B., Sümegi B. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem. Pharmacol. 59:2000;937-945. (2000).
43. Szabó C., Dawson V.L. Role of poly(ADP-ribose)synthetase in inflamation and ischemia-reperfusion. Trends Pharmacol. Sci. 19:1998;287-298.
44. st AACR Annual Meeting Proc. Abstr. 1281 (2000).
45. Tredici G., Cavaletti G., Petruccioli M.G., Fabbrica D., Tedeschi M., Venturino P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology. 15:1994;701-704.
46. Uozumi J., Ueda T., Yasumasu T., Koikawa J., Kumazawa J. Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int. Urol. Nephrol. 24:1992;549-553.
47. Vock E.H., Lutz W.K., Hormes P., Hoffmann H.D., Vamvakas S. Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X- 100, and gamma-irradiation. Mutat. Res. 413:1998;83-94.
48. Zha H., Aime-Sempe C., Sato T., Reed J.C. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J. Biol. Chem. 271:1996;7440-7444.
49. Zhang J., Lindup E. Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem. Pharmacol. 45:1993;2215-2222.